Concurrent moxifloxacin-induced liver injury and toxic epidermal necrolysis after immune checkpoint inhibition: a case report and literature review
Abstract
BACKGROUND: The widespread clinical use of immune checkpoint inhibitors (ICIs) in oncology has been accompanied by an increased incidence of immune-related adverse events (irAEs). When ICIs are combined with other medications, the risk of drug-induced liver injury (DILI) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) may be amplified. Moxifloxacin, a fluoroquinolone antibiotic known to cause hepatic injury and cutaneous adverse reactions, is an uncommon culprit in the setting of prior ICI therapy but warrants vigilance for its potential to precipitate acute DILI and TEN.
METHODS: We report a case of a 58-year-old man with lung adenocarcinoma who achieved a major pathological response after neoadjuvant tislelizumab combined with carboplatin and docetaxel. Postoperatively, he developed severe pneumonia and was treated with moxifloxacin and vancomycin. He subsequently developed severe DILI and TEN. Causality assessment implicated moxifloxacin as the principal offending agent, with a RUCAM score of 9 (probable) and an ALDEN score of 5 (probable). In addition, we conducted a systematic review of 28 published cases of concurrent DILI and SJS/TEN to characterize drug classes and clinical features.
RESULTS: Ten days after initiation of moxifloxacin, the patient developed synchronous DILI and TEN, suggesting that prior immunotherapy may have lowered the threshold for immune tolerance and amplified T cell-mediated, drug-induced immune responses. At 23 months…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.